Disease Modification in Myelofibrosis: An Elusive Goal?

J Clin Oncol. 2022 Apr 10;40(11):1147-1154. doi: 10.1200/JCO.21.02246. Epub 2022 Jan 27.

Authors

Pankit Vachhani¹, Srdan Verstovsek², Prithviraj Bose²

Affiliations

¹ Department of Medicine, Division of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, AL.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Goals
Humans
Janus Kinase 2
Primary Myelofibrosis* / therapy

Substances

Janus Kinase 2

Grants and funding